Issues in the design of trials of therapies for subjects with human immunedeficiency virus infection that use plasma RNA level as an outcome

Journal of Infectious Diseases

Volumn 175, Issue 3, 1997, Pages 576-582

  Raboud, J M ^a   Montaner, J S G ^b   Rae, S ^b   Conway, B ^b   Singer, J ^b   Schechter, M T ^b  

^a Canadian HIV Trials Network   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; HYDROXYUREA; LAMIVUDINE; NEVIRAPINE; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; META ANALYSIS; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RNA ANALYSIS; SAMPLING; TREATMENT OUTCOME;

EID: 0031035882     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/175.3.576     Document Type: Article

References (25)

1. Lagakos SW, Hoth DF. Surrogate markers in AIDS: where are we? Where are we going? Ann Intern Med 1992;116:599-601.
2. Machado SG, Gail MH, Ellenberg SS. On the use of laboratory markers as surrogates for clinical end points in the evaluation of treatment for HIV infection. J Acquir Immune Defic Syndr 1990;3:1065-73.
3. Moss AR. Laboratory markers as potential surrogates for clinical outcomes in AIDS trials. J Acquir Immune Defic Syndr 1990;3(suppl 2): S69-71.
4. Amato DA, Lagakos SW. Considerations in the selection of end points for AIDS clinical trials. J Acquir Immune Defic Syndr 1990;3(suppl 2):S64-8.
5. + lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med 1993;118:674-80.
6. Lin DY, Fischl MA, Schoenfeld DA. Evaluating the role of CD4 lymphocyte counts as surrogate endpoints in human immunodeficiency virus clinical trials. Stat Med 1993;12:835-42.
7. Finkelstein DM, Schoenfeld DA, eds. AIDS clinical trials. New York: John Wiley & Sons, 1995.
8. Montaner JSG, Wainberg M, Rachlis A, et al. A double blind comparative trial of didanosine versus continued zidovudine therapy for moderately advanced human immunodeficiency virus infection. Ann Intern Med 1995;123:561-71.
9. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial comparing immediate and deferred zidovudine in asymptomatic HIV infection. Lancet 1994;343:871-81.
10. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995;333:1534-9.
11. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995;333:1528-33.
12. + cells per cubic millimeter. N Engl J Med 1995;333:1662-9.
13. Lange JMA. Current HIV clinical trial design issues. J Acquir Immune Defic Syndr 1995; 10(suppl 1):S47-51.
14. Conway B, Montaner JSG, Raboud JM, et al. Immunological and virological effects of combination therapy with ZDV plus ddl or ddC [abstract]. Presented at the 3rd Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 1996.
15. 3 [abstract Mo.B.294]. In: Program and abstracts: XI International Conference on AIDS, Vancouver, Canada, July 1996.
16. Montaner JSG, Zala C, Conway B, et al. A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV Trials Network Protocol 080. J Infect Dis 1997;175:801-6.
17. Rouleau D, Conway B, Raboud JM, et al. A pilot open label study of the antiviral effect of stavudine (d4T) and lamivudine (3TC) in advanced HIV disease [abstract We.B.3137]. In: Program and abstracts: XI International Conference on AIDS, Vancouver, Canada, July 1996.
18. Raboud JM, Montaner JSG, Conway B, et al. Variation in plasma RNA levels, CD4 cell counts and p24 antigen levels in clinically stable men with human immunodeficiency virus infection. J Infect Dis 1996;174: 191-4.
19. Dawson JD. Comparing treatment groups on the basis of slopes, areasunder-the-curve and other summary measures. Drug Information J 1994; 28:723-32.
20. Rosner B. Fundamentals of biostatistics. Boston: Duxbury Press, 1982.
21. Diggle PJ, Liang KY, Zeger SL. Analysis of longitudinal data. Oxford, UK: Clarendon Press, 1994.
22. Schoenfeld DA, Finkelstein DM, Richman DD. Designing phase II studies of chemotherapy for HIV infection using CD4 as an end-point. AIDS 1993;7:955-8.
23. Raboud JM, Montaner JSG, Thorne A, Singer J, Schechter MT. The impact of missing data due to dropouts on estimates of the treatment effect in a randomized trial of antiretroviral therapy for HIV-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12:46-55.
24. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963-74.
25. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.